Literature DB >> 8987076

Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapeptide. A novel example of an excipient-induced oxidation.

D C Dubost1, M J Kaufman, J A Zimmerman, M J Bogusky, A B Coddington, S M Pitzenberger.   

Abstract

PURPOSE: To elucidate the structure of a degradation product arising from a lyophilized formulation of a cyclic heptapeptide, and to provide a mechanism to account for its formation.
METHODS: Preparative HPLC was used to isolate the degradate in quantities sufficient for structural studies. A structure assignment was made on the basis of the compounds spectroscopic properties (UV, MS, NMR) and the results of amino acid analysis.
RESULTS: The degradate was identified as a benzaldehyde derivative arising from the oxidative deamination of an aminomethyl phenylalanine moiety. The extent of formation of this product is influenced by the amount of mannitol used as an excipient in the formulation. A mechanism is proposed whereby reducing sugar impurities in mannitol act as an oxidizing agent via the intermediacy of Schiff base adducts which subsequently undergo tautomerization and hydrolysis.
CONCLUSIONS: Reducing sugar impurities in mannitol are responsible for the oxidative degradation of the peptide via a mechanism that involves Schiff base intermediates. This mechanism may be a potential route of degradation of other arylmethyl amines in mannitol-based formulations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8987076     DOI: 10.1023/a:1016024923002

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Influence of peroxide impurities in polyethylene glycols on drug stability.

Authors:  J W McGinity; J A Hill; A L La Via
Journal:  J Pharm Sci       Date:  1975-02       Impact factor: 3.534

2.  Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.

Authors:  G D Hartman; M S Egbertson; W Halczenko; W L Laswell; M E Duggan; R L Smith; A M Naylor; P D Manno; R J Lynch; G Zhang
Journal:  J Med Chem       Date:  1992-11-27       Impact factor: 7.446

Review 3.  Stability of protein pharmaceuticals.

Authors:  M C Manning; K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

4.  Degradation of O6-benzylguanine in aqueous polyethylene glycol 400 (PEG 400) solutions: concerns with formaldehyde in PEG 400.

Authors:  D S Bindra; T D Williams; V J Stella
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

5.  Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation.

Authors:  T Geiger; S Clarke
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

6.  Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.

Authors:  D R Ramjit; J J Lynch; G R Sitko; M J Mellott; M A Holahan; I I Stabilito; M T Stranieri; G Zhang; R J Lynch; P D Manno
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

  6 in total
  4 in total

Review 1.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 2.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

Review 3.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 4.  Rational design of stable lyophilized protein formulations: some practical advice.

Authors:  J F Carpenter; M J Pikal; B S Chang; T W Randolph
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.